LI
BLFS icon

Leap Investments’s BioLife Solutions BLFS Stock Holding History

Leap Investments’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,530
Closed -$175K – 433
2019
Q3 		$175K Buy
+10,530
New +$198K 0.09% 320

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Leap Investments's BLFS Position: Q4 2019 in Review

Leap Investments sold out of BioLife Solutions (BLFS) in Q4 2019, closing a stake of 10,530 shares — an estimated $175K sold.

Leap Investments first reported a position in BLFS in Q3 2019 and held it in 1 quarter. The position peaked at $175K in Q3 2019. 80 funds tracked by Wall St. Rank hold BLFS as of Q4 2019.

  • Leap Investments reported no remaining BioLife Solutions position as of Q4 2019 after selling out during the quarter.
  • Leap Investments sold 10,530 BioLife Solutions shares in Q4 2019, an estimated $175K.
  • Leap Investments first reported a position in BioLife Solutions in Q3 2019 and held it in 1 quarter.
  • Leap Investments's BioLife Solutions position peaked at $175K in Q3 2019.
  • 80 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.